Currently, a global open-label expansion cohort of REACH-2 is ongoing, initiated to study ramucirumab in patients with advanced HCC and baseline AFP ≥400 ng/mL following a non-sorafenib based systemic therapy (NCT02435433) [94]. This evidence concerns the gene AFP and hepatocellular carcinoma.